Research programme: Cell therapies - Ambys Medicines
Latest Information Update: 28 Jun 2026
At a glance
- Originator Ambys Medicines
- Class Cell therapies; Gene therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver disorders
Most Recent Events
- 28 Jun 2026 No recent reports of development identified for preclinical development in Liver-disorders in USA (Parenteral)
- 24 May 2022 Preclinical trials in Liver disorders in USA (Parenteral)